Eccrine syringosquamous metaplasia (Q90209): Difference between revisions

← Older edit

@@ Property / CURIE @@
+CID11:ID_407987403
@@ Property / CURIE: CID11:ID_407987403 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-ID_407987403
@@ Property / Canary Token: dki-india-ID_407987403 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 17:09, 15 August 2026

Eccrine syringosquamous metaplasia describes a distinctive microscopic finding of eccrine duct damage in which an insult, most commonly cytotoxic chemotherapy, has resulted in a transformation from the normal cuboidal to squamous epithelium, which may simulate squamous cell carcinoma. Patients present with erythematous papules, often in a generalised distribution and sometimes with vesicles and pustules. It may also present with acral erythema. Drugs implicated include cytarabine, doxorubicin, cis-platinum and protein kinase inhibitors.

Language	Label	Description	Also known as
default for all languages	ID_407987403
English	Eccrine syringosquamous metaplasia	Eccrine syringosquamous metaplasia describes a distinctive microscopic finding of eccrine duct damage in which an insult, most commonly cytotoxic chemotherapy, has resulted in a transformation from the normal cuboidal to squamous epithelium, which may simulate squamous cell carcinoma. Patients present with erythematous papules, often in a generalised distribution and sometimes with vesicles and pustules. It may also present with acral erythema. Drugs implicated include cytarabine, doxorubicin, cis-platinum and protein kinase inhibitors.